Browse the evidence

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and other comparators in patients with type 2 diabetes and obesity.

Tirzepatide is a dual-acting hormone medication (GIP/GLP-1) that offers even greater weight loss than semaglutide (up to 21% in trials). It is administered as a once-weekly injection, starting at a low dose and increasing every 4 weeks. It is particularly effective for patients with type 2 diabetes and obesity, improving both blood sugar and weight significantly more than other comparators.

A pragmatic prescribing pathway for liraglutide 3.0 mg using multiple stopping rules (≥5% weight loss at 16 weeks, ≥10% at 32 weeks, and ≥15% at 52 weeks) significantly increases the proportion of adults with obesity achieving ≥15% weight loss compared to standard specialist weight management services alone.

If you have a BMI of 35 or higher and conditions like high blood pressure or sleep apnea, ask your doctor about a specialized weight management program that includes liraglutide 3.0 mg. This medication is taken as a daily injection, starting at a low dose and increasing to 3 mg. A key part of this approach is 'stopping rules': if you don't lose enough weight at specific check-ups, the medication is stopped to save costs and avoid unnecessary side effects. This method helps ensure that only those who benefit continue treatment, leading to much better long-term weight loss results than lifestyle changes alone.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) are the most effective pharmacological interventions for weight loss, producing significantly greater total body weight loss than other FDA-approved anti-obesity medications.

If you have obesity, lifestyle changes alone are rarely enough for long-term success due to your body's biological resistance. Semaglutide (Ozempic/Wegovy) is currently the most effective drug available, helping patients lose an average of 12.4% of their body weight when combined with diet and exercise. It requires a weekly injection. If cost is a barrier, discuss insurance coverage (sometimes available for diabetes) or cheaper alternatives like phentermine-topiramate with your doctor. The goal is to find a regimen you can tolerate and afford for the long term.

Phentermine-topiramate extended-release is a highly effective alternative for weight loss, particularly for patients who cannot use GLP-1 agonists, achieving high percentages of total body weight loss.

If GLP-1 drugs are too expensive or not covered by insurance, Phentermine-topiramate (Qsymia) is a strong alternative that can help you lose around 10-11% of your body weight. It is a daily pill. Be aware of potential side effects like irritability or sleep issues, which can often be managed by adjusting the dose or taking the medication earlier in the day. It is contraindicated if you have uncontrolled high blood pressure or a history of seizures.

GLP-1 receptor agonists (e.g., Liraglutide 3.0mg) and SGLT2 inhibitors significantly reduce body weight and improve glycemic control in T2D patients, with GLP-1 agonists showing superior weight loss compared to other drug classes.

If lifestyle changes are not enough, ask your doctor about GLP-1 receptor agonists (like Liraglutide) or SGLT2 inhibitors. These drugs help you lose weight and control blood sugar, unlike older diabetes medications that cause weight gain. GLP-1s are particularly effective for weight loss.

Combining GLP-1 RAs with basal insulin provides superior glycemic management and cardiorenal protection compared to using either therapy alone, while mitigating the side effects of high-dose GLP-1 RAs.

If you are struggling to control your blood sugar with just a GLP-1 shot (like Ozempic) or just basal insulin, combining them is often the most effective strategy. New 'fixed-ratio' combination pens allow you to inject both medications in a single shot. This approach lowers your A1C more effectively than either drug alone, protects your heart and kidneys, and often reduces the side effects (like nausea) associated with high doses of GLP-1 RAs.

GLP-1 receptor agonists (GLP1-RA) and SGLT2 inhibitors (SGLT2-i) are effective interventions for obesity-related cardiometabolic complications by reducing body weight and addressing pathophysiological derangements.

If lifestyle changes are insufficient, discuss GLP-1 RAs or SGLT2 inhibitors with your doctor. These medications are now recognized as essential tools for managing obesity and its heart/kidney risks, not just for diabetes.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.

GLP-1 receptor agonists like semaglutide (2.4 mg weekly) are highly effective for weight loss in obese, non-diabetic adults, achieving ~15% body weight reduction. They work by suppressing appetite via brain receptors. Be aware of common side effects like nausea and the likelihood of weight regain if treatment stops, suggesting a need for long-term management.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.

Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.

Subcutaneous semaglutide at 2.4 mg once weekly produces clinically significant weight loss (mean 14.9–17.4% reduction) in adults with obesity or overweight, with gastrointestinal side effects being the primary limiting factor.

For adults with obesity, weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle changes leads to substantial weight loss (approx. 15%). The main barrier is gastrointestinal side effects like nausea, which are usually mild and do not prevent weight loss. If injections are not preferred, oral semaglutide is an alternative, though subcutaneous administration may yield slightly greater weight loss.

Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (14 mg) effectively reduce body weight and HbA1c in patients with Type 2 Diabetes, with subcutaneous administration showing greater weight loss than oral administration in indirect comparisons.

For patients with Type 2 Diabetes, both subcutaneous (0.5-1.0 mg weekly) and oral (14 mg daily) semaglutide effectively reduce weight and blood sugar. Subcutaneous administration appears to produce greater weight loss than the oral form, though both are superior to other diabetes medications.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) facilitates the largest reduction in body weight and increases in health-related quality of life (QoL) among Type 2 Diabetes medications.

If weight loss and quality of life are your primary goals, Tirzepatide is the most effective medication identified in this analysis. It offers greater weight reduction and QoL improvements than standard GLP-1 RAs, though it may cause gastrointestinal side effects.

GLP-1 receptor agonists (GLP-1RA) such as semaglutide and liraglutide produce significant weight loss (≥10%) and cardiovascular benefits in adults with obesity.

GLP-1 receptor agonists like semaglutide are highly effective for weight loss, often achieving 10% or more body weight reduction, and also provide cardiovascular benefits. These medications are available in both injectable and oral forms, offering flexibility for long-term management of obesity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial, dose-dependent weight loss in adults with obesity (mean 15-21% over 72 weeks) and superior glycemic control compared to placebo and other GLP-1 agonists.

Tirzepatide is a once-weekly injection that targets two gut hormones (GIP and GLP-1) to reduce appetite and improve blood sugar. In clinical trials, it led to an average weight loss of 15-21% over 72 weeks, significantly outperforming placebo and other GLP-1 drugs like Semaglutide. It is prescribed for adults with obesity (BMI ≥30, or ≥27 with comorbidities) and requires a slow dose escalation to manage gastrointestinal side effects.

GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.

Semaglutide 2.4 mg administered once weekly via subcutaneous injection significantly reduces body weight in adults with obesity or overweight when used as an adjunct to lifestyle modifications.

If you have obesity or overweight with a related health condition, ask your doctor about Semaglutide 2.4 mg. It is taken as a once-weekly injection alongside diet and exercise. Expect significant weight loss (around 15% in trials), but be prepared for temporary stomach issues like nausea, which usually get better over time.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors provide cardiovascular and renal benefits independent of glycemic control, with GLP-1 RAs being preferred for obesity/T2D and SGLT2 inhibitors for T2D with heart failure.

If you have T2D and obesity, ask your doctor about GLP-1 agonists (like Semaglutide or Liraglutide). They help with weight loss and protect your heart and kidneys, even if your blood sugar is already controlled. If you also have heart failure, SGLT2 inhibitors might be better.

GLP-1 receptor agonists lower plasma glucose and suppress appetite, providing significant benefits for glycemic control and weight loss in type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, GLP-1 receptor agonists are a proven, first-line treatment option that effectively lowers blood sugar and aids weight loss. Discuss these options with your healthcare provider to see if they are appropriate for your specific health profile.

Liraglutide 3.0 mg, a GLP-1 analogue, promotes weight loss and improves metabolic parameters through mechanisms involving hypothalamic energy balance regulation, glucose-dependent insulin stimulation, and slowed gastric emptying.

Liraglutide 3.0 mg works by mimicking a natural hormone that regulates hunger, insulin, and digestion. It is taken as a daily injection, starting at a low dose and increasing weekly to reduce side effects like nausea. It is contraindicated for those with specific thyroid cancer histories.

GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.

For significant weight loss, GLP-1 RAs like semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) are highly effective, producing 15% or more body weight loss in clinical trials. They work by reducing appetite and slowing digestion. While side effects like nausea are common, they often improve over time. These drugs are most effective when combined with lifestyle changes.

Pharmacological weight loss therapy is indicated for BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidities, aiming for ≥ 5% weight loss within 3-4 months of reaching the target dose.

If lifestyle changes alone aren't enough and your BMI is high (≥30 or ≥27 with health issues), ask your doctor about approved weight-loss medications. These are used alongside lifestyle changes and aim for at least 5% weight loss within a few months of reaching the full dose.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (5-15%) and improve cardiometabolic risk factors in adults with obesity, with efficacy increasing with higher doses.

If lifestyle changes alone haven't led to significant weight loss, GLP-1 or dual agonist medications can help you lose 5-15% of your body weight and improve your blood sugar and heart health. These are prescription medications that work by mimicking hormones that control hunger. You will need to start with a low dose and slowly increase it to avoid stomach side effects like nausea.

Phentermine/topiramate combination therapy produces significant weight loss (up to 8.6% vs placebo) and improves metabolic markers, but is contraindicated in patients with unstable cardiovascular disease.

This combination medication can help you lose weight and improve your metabolic health. It works by suppressing appetite and increasing energy expenditure. Because it can affect heart rate and blood pressure, it is not suitable for everyone, especially those with heart conditions. You must start with a low dose and increase it slowly to minimize side effects like tingling or dry mouth.